75.51
price up icon0.39%   0.29
after-market 시간 외 거래: 75.51
loading
전일 마감가:
$75.22
열려 있는:
$75.73
하루 거래량:
594.12K
Relative Volume:
0.47
시가총액:
$3.70B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-25.20
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+2.94%
1개월 성능:
+2.44%
6개월 성능:
+53.63%
1년 성능:
+69.15%
1일 변동 폭
Value
$74.34
$76.25
1주일 범위
Value
$72.96
$78.78
52주 변동 폭
Value
$36.93
$80.99

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name
명칭
Soleno Therapeutics Inc
Name
전화
650-213-8444
Name
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Name
직원
92
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
SLNO's Discussions on Twitter

SLNO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SLNO
Soleno Therapeutics Inc
75.51 3.70B 0 -38.99M -24.94M -2.9966
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-05 재개 Stifel Buy
2024-12-02 재확인 Robert W. Baird Outperform
2024-12-02 재확인 Stifel Buy
2024-09-03 개시 H.C. Wainwright Buy
2024-05-10 개시 Robert W. Baird Outperform
2024-02-05 개시 Piper Sandler Overweight
2024-01-23 개시 Stifel Buy
2023-11-21 재개 Guggenheim Buy
2020-09-29 개시 Guggenheim Buy
2020-01-10 개시 Craig Hallum Buy
2019-12-23 개시 Oppenheimer Outperform
2018-02-13 재확인 Maxim Group Buy
모두보기

Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스

pulisher
Jun 06, 2025

Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 05, 2025

Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com

Jun 05, 2025
pulisher
Jun 04, 2025

Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 27, 2025

Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India

May 27, 2025
pulisher
May 26, 2025

EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

(SLNO) Trading Report - news.stocktradersdaily.com

May 25, 2025
pulisher
May 23, 2025

Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan

May 22, 2025
pulisher
May 22, 2025

BCE Inc: Stock Forecast & Analysis - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia

May 22, 2025
pulisher
May 21, 2025

Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia

May 21, 2025
pulisher
May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 20, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times

May 20, 2025
pulisher
May 20, 2025

VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 20, 2025
pulisher
May 19, 2025

Company News for May 19, 2025 - The Globe and Mail

May 19, 2025
pulisher
May 18, 2025

Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World

May 18, 2025
pulisher
May 15, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - GlobeNewswire

May 13, 2025
pulisher
May 12, 2025

SLNO FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 11, 2025

Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Insider Monkey

May 11, 2025
pulisher
May 11, 2025

11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey

May 11, 2025
pulisher
May 10, 2025

Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term - The Globe and Mail

May 10, 2025

Soleno Therapeutics Inc (SLNO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):